Literature DB >> 20558726

BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.

Aurore Keutgens1, Xin Zhang, Kateryna Shostak, Isabelle Robert, Sabine Olivier, Alain Vanderplasschen, Jean-Paul Chapelle, Patrick Viatour, Marie-Paule Merville, Françoise Bex, André Gothot, Alain Chariot.   

Abstract

The oncogenic protein BCL-3 activates or represses gene transcription through binding with the NF-kappaB proteins p50 and p52 and is degraded through a phospho- and GSK3-dependent pathway. However, the mechanisms underlying its degradation remain poorly understood. Yeast two-hybrid analysis led to the identification of the proteasome subunit PSMB1 as a BCL-3-associated protein. The binding of BCL-3 to PSMB1 is required for its degradation through the proteasome. Indeed, PSMB1-depleted cells are defective in degrading polyubiquitinated BCL-3. The N-terminal part of BCL-3 includes lysines 13 and 26 required for the Lys(48)-linked polyubiquitination of BCL-3. Moreover, the E3 ligase FBW7, known to polyubiquitinate a variety of substrates phosphorylated by GSK3, is dispensable for BCL-3 degradation. Thus, our data defined a unique motif of BCL-3 that is needed for its recruitment to the proteasome and identified PSMB1 as a key protein required for the proteasome-mediated degradation of a nuclear and oncogenic IkappaB protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558726      PMCID: PMC2919145          DOI: 10.1074/jbc.M110.112128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Identification of the familial cylindromatosis tumour-suppressor gene.

Authors:  G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

3.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

Authors:  Markus Welcker; Jeffrey Singer; Keith R Loeb; Jonathan Grim; Andrew Bloecher; Mark Gurien-West; Bruce E Clurman; James M Roberts
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

4.  Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.

Authors:  P C Cogswell; D C Guttridge; W K Funkhouser; A S Baldwin
Journal:  Oncogene       Date:  2000-02-24       Impact factor: 9.867

5.  Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells.

Authors:  M Arsura; F Mercurio; A L Oliver; S S Thorgeirsson; G E Sonenshein
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease.

Authors:  Momoko Nishikori; Yoshitomo Maesako; Chiyoko Ueda; Masayuki Kurata; Takashi Uchiyama; Hitoshi Ohno
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

7.  Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3.

Authors:  Patrick Viatour; Sylvie Legrand-Poels; Carine van Lint; Michael Warnier; Marie-Paule Merville; Jacques Gielen; Jacques Piette; Vincent Bours; Alain Chariot
Journal:  J Biol Chem       Date:  2003-09-12       Impact factor: 5.157

8.  Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.

Authors:  I Robert; M Aussems; A Keutgens; X Zhang; B Hennuy; P Viatour; G Vanstraelen; M-P Merville; J-P Chapelle; L de Leval; F Lambert; E Dejardin; A Gothot; A Chariot
Journal:  Oncogene       Date:  2009-02-16       Impact factor: 9.867

9.  Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways.

Authors:  Julie L Hanson; Vasiliki Anest; Julie Reuther-Madrid; Albert S Baldwin
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

10.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

View more
  14 in total

1.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

2.  Nitric oxide increases lysine 48-linked ubiquitination following arterial injury.

Authors:  Chris S Oustwani; Nick D Tsihlis; Ashley K Vavra; Qun Jiang; Janet Martinez; Melina R Kibbe
Journal:  J Surg Res       Date:  2011-06-15       Impact factor: 2.192

3.  MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.

Authors:  K Shostak; F Patrascu; S I Göktuna; P Close; L Borgs; L Nguyen; F Olivier; A Rammal; H Brinkhaus; M Bentires-Alj; J-C Marine; A Chariot
Journal:  Cell Death Differ       Date:  2014-01-31       Impact factor: 15.828

4.  Bcl2-associated athanogene 3 interactome analysis reveals a new role in modulating proteasome activity.

Authors:  Ying Chen; Li-Na Yang; Li Cheng; Shun Tu; Shu-Juan Guo; Huang-Ying Le; Qian Xiong; Ran Mo; Chong-Yang Li; Jun-Seop Jeong; Lizhi Jiang; Seth Blackshaw; Li-Jun Bi; Heng Zhu; Sheng-Ce Tao; Feng Ge
Journal:  Mol Cell Proteomics       Date:  2013-07-03       Impact factor: 5.911

5.  Changes in leukocyte gene expression profiles induced by antineoplastic chemotherapy.

Authors:  Rebeca González-Fernández; Manuel Morales; Julio Avila; Pablo Martín-Vasallo
Journal:  Oncol Lett       Date:  2012-04-03       Impact factor: 2.967

6.  The tumor promoter and NF-κB modulator Bcl-3 regulates splenic B cell development.

Authors:  Xiaoren Zhang; Andrea Paun; Estefania Claudio; Hongshan Wang; Ulrich Siebenlist
Journal:  J Immunol       Date:  2013-11-15       Impact factor: 5.422

Review 7.  Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Tumour Biol       Date:  2012-03-06

Review 8.  Role of Bcl-3 in solid tumors.

Authors:  Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  Mol Cancer       Date:  2011-12-23       Impact factor: 27.401

9.  Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease.

Authors:  Tejaswita M Karve; Amrita K Cheema
Journal:  J Amino Acids       Date:  2011-07-21

10.  Genes involved in type 1 diabetes: an update.

Authors:  Marina Bakay; Rahul Pandey; Hakon Hakonarson
Journal:  Genes (Basel)       Date:  2013-09-16       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.